CareDx, Inc. (CDNA)

NGM – Real vaqt narxi. Valyuta: USD

21.40

-0.15 (-0.70%)

Yopilishda: May 12, 2026, 4:00 PM EDT

11.05.2026

CareDx Announces Dismissal of 2021 Qui Tam Suit

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the dismissal of a qui tam action filed against the Company. On April 23, 2026, the United States District Court for the Eastern District of New York issued an order dismissing the matter. Ther.

04.05.2026

CareDx, Inc. (CDNA) Q1 2026 Earnings Call Transcript

01.05.2026

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the award of inducement grants. On April 30, 2026, as an inducement material to acceptance of employment with CareDx, 23 new employees were awarded restricted stock units (RSUs) for an aggreg.

28.04.2026

CareDx (CDNA) Q1 Earnings and Revenues Top Estimates

CareDx (CDNA) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.09 per share a year ago.

28.04.2026

CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it has entered into a definitive agreement to acquire Naveris, a commercial stage precision oncology diagnostics company with a highly differentiated and Medicare-reimbursed, blood‑based monito.

28.04.2026

CareDx Announces First Quarter 2026 Financial Results

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights Revenue of $118 million, an increase of 39% year-over-year Testing services revenue of $91 m.

21.04.2026

CareDx Announces Presentation of More Than 50 Abstracts Including 16 Oral Presentations at the International Society for Heart and Lung Transplantation's 46th Annual Meeting

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced its participation at the International Society of Heart and Lung Transplantation (ISHLT) 2026 Annual Meeting, taking place April 22–25 in Toronto, Canada. The real-world clinical use and scient.

Videolar

No Data

There is no data to display

CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it has entered into a definitive agreement to acquire Naveris, a commercial stage precision oncology diagnostics company with a highly differentiated and Medicare-reimbursed, blood‑based monito.

28.04.2026

CareDx Announces First Quarter 2026 Financial Results

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights Revenue of $118 million, an increase of 39% year-over-year Testing services revenue of $91 m.

CareDx, Inc. (CDNA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

CareDx, Inc. (CDNA)

CareDx Announces Dismissal of 2021 Qui Tam Suit

CareDx, Inc. (CDNA) Q1 2026 Earnings Call Transcript

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CareDx (CDNA) Q1 Earnings and Revenues Top Estimates

CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing

CareDx Announces First Quarter 2026 Financial Results

CareDx Announces Presentation of More Than 50 Abstracts Including 16 Oral Presentations at the International Society for Heart and Lung Transplantation's 46th Annual Meeting

Videolar

No Data

Press-relizlar

CareDx Announces Dismissal of 2021 Qui Tam Suit

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing

CareDx Announces First Quarter 2026 Financial Results

CareDx Announces Dismissal of 2021 Qui Tam Suit

CareDx, Inc. (CDNA) Q1 2026 Earnings Call Transcript

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CareDx (CDNA) Q1 Earnings and Revenues Top Estimates

CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing

CareDx Announces First Quarter 2026 Financial Results

CareDx Announces Presentation of More Than 50 Abstracts Including 16 Oral Presentations at the International Society for Heart and Lung Transplantation's 46th Annual Meeting

Videolar

No Data

Press-relizlar

CareDx Announces Dismissal of 2021 Qui Tam Suit

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing

CareDx Announces First Quarter 2026 Financial Results

Search stocks

CareDx, Inc. (CDNA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

CareDx, Inc. (CDNA)

CareDx Announces Dismissal of 2021 Qui Tam Suit

CareDx, Inc. (CDNA) Q1 2026 Earnings Call Transcript

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CareDx (CDNA) Q1 Earnings and Revenues Top Estimates

CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing

CareDx Announces First Quarter 2026 Financial Results

CareDx Announces Presentation of More Than 50 Abstracts Including 16 Oral Presentations at the International Society for Heart and Lung Transplantation's 46th Annual Meeting

Videolar

No Data

Press-relizlar

CareDx Announces Dismissal of 2021 Qui Tam Suit

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing

CareDx Announces First Quarter 2026 Financial Results

CareDx Announces Dismissal of 2021 Qui Tam Suit

CareDx, Inc. (CDNA) Q1 2026 Earnings Call Transcript

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CareDx (CDNA) Q1 Earnings and Revenues Top Estimates

CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing

CareDx Announces First Quarter 2026 Financial Results

CareDx Announces Presentation of More Than 50 Abstracts Including 16 Oral Presentations at the International Society for Heart and Lung Transplantation's 46th Annual Meeting

Videolar

No Data

Press-relizlar

CareDx Announces Dismissal of 2021 Qui Tam Suit

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing

CareDx Announces First Quarter 2026 Financial Results